|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Double-stranded DNA in exosomes: a novel biomarker in cancer detection显示文摘 | Basant Kumar Thakur Haiying Zhang Annette Becker Irina Matei Yujie Huang Bruno Costa-Silva Yan Zheng Ayuko Hoshino Helene Brazier Jenny Xiang Caitlin Williams Ruth Rodriguez-Barrueco Jose M Silva Weijia Zhang Stephen Hearn Olivier Elemento Navid Paknejad Katia Manova-Todorova Karl Welte Jacqueline Bromberg Hector Peinado David Lyden | 2014 | Cell Research2014，24，6： | 98 |
| 2 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 3 | Predictors of suboptimal bowel preparation in asymptomatic patients undergoing average-risk screening colonoscopy显示文摘AIM To identify risk factors for a suboptimal preparation among a population undergoing screening or surveillance colonoscopy.METHODS Retrospective review of the University of Michigan and Veteran's Administration(VA) Hospital records from 2009 to identify patients age 50 and older who underwent screening or surveillance procedure and had resection of polyps less than 1 cm in size and no more than 2 polyps. Patients with inflammatory bowel disease or a family history of colorectal cancer were excluded. Suboptimal procedures were defined as procedure preparations categorized as fair, poor or inadequate by the endoscopist. Multivariable logistic regression was used to identify predictors of suboptimal preparation.RESULTS Of 4427 colonoscopies reviewed, 2401 met our inclusion criteria and were analyzed. Of our population, 16% had a suboptimal preparation. African Americans were 70% more likely to have a suboptimal preparation(95%CI: 1.2-2.4). Univariable analysis revealed that narcotic and tricyclic antidepressants(TCA) use, diabetes, prep type, site(VA vs non-VA), and presence of a gastroenterology(GI) fellow were associated with suboptimal prep quality. In a multivariable model controlling for gender, age, ethnicity, procedure site and presence of a GI fellow, diabetes [odds ratio(OR) = 2.3; 95%CI: 1.6-3.2], TCA use(OR = 2.5; 95%CI: 1.3-4.9), narcotic use(OR = 1.7; 95%CI: 1.2-2.5) and Miralax-Gatorade prep vs 4L polyethylene glycol 3350(OR = 0.6; 95%CI: 0.4-0.9) were associated with a suboptimal prep quality. CONCLUSION Diabetes, narcotics use and TCA use were identified as predictors of poor preparation in screening colonoscopies while Miralax-Gatorade preps were associated with better bowel preparation. | Shail M Govani Eric E Elliott Stacy B Menees Stephanie L Judd Sameer D Saini Constantinos P Anastassiades Annette L Urganus Suzanna J Boyce Philip S Schoenfeld | 2016 | World Journal of Gastrointestinal Endoscopy2016，8，17： | 7 |
| 4 | 老年人尿失禁的流行病学和病因学显示文摘尿失禁是老年人的一个普遍问题。22%~34%的妇女声称患过尿失禁。其患病率随尿失禁程度和询问方式不同而变化很大。65岁以上妇女按尿失禁保守定义即常见的尿失禁或按限制定义即压迫性尿失禁,其患病率为10%~30%。这一患病率在长期疗养院内还要高且随被检人群的年龄上升而增高。男性发病率为25%或低于妇女。 | Edward J.McGuire Martin Resnick S.V.Yalla Ruth Kirschner-Hermanns Enrique Broseta Cath McGrother Christa Müller Annette Welz-Barth G.Ch.Fischer Johann Mattelaer 李小刚 | 1999 | 德国医学1999，16，6： | 4 |
| 5 | Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage Ⅱ and Ⅲ rectal adenocarcinoma:The Freiburg experience(1989-2002)显示文摘AIM:To evaluate the long-term outcome of standard5-FU based adjuvant or neoadjuvant radiochemotherapyand to identify the predictive factors,especially anemiabefore and after radiotherapy as well as hemoglobinincrease or decrease during radiotherapy.METHODS:Two hundred and eighty-six patientswith Union International Contre Cancer(UICC)stageⅡ and Ⅲ rectal adenocarcinomas,who underwentresection by conventional surgical techniques(lowanterior or abdominoperineal resection),receivedeither postoperative(n=233)or preoperative(n=53)radiochemotherapy from January 1989 until July 2002.Overall survival(OAS),cancer-specific survival(CSS),disease-free survival(DFS),local-relapse-free(LRS)and distant-relapse-free survival(DRS)were evaluatedusing Kaplan-Meier,Log-rank test and Cox's proportionalhazards as statistical methods.Multivariate analysis wasused to identify prognostic factors.Median follow-uptime was 8 years.RESULTS:Anemia before radiochemotherapy was anindependent prognostic factor for improved DFS(riskratio 0.76,P=0.04)as well as stage,grading,R status(free radial margins),type of surgery,carcinoembryonicantigen(CEA)levels,and gender.The univariate analysisrevealed that anemia was associated with impaired LRS (better local control)but with improved DFS.In contrast,hemoglobin decrease during radiotherapy was anindependent risk factor for DFS(risk ratio 1.97,P=0.04).During radiotherapy,only 30.8% of RO-resected patientssuffered from hemoglobin decrease compared to 55.6%if R1/2 resection was performed(P=0.04).The 5-yearOAS,CSS,DFS,LRS and DRS were 47.0%,60.0%,41.4%,67.2%,and 84.3%,respectively.Significantdifferences between preoperative and postoperativeradiochemotherapy were not found.CONCLUSION:Anemia before radiochemotherapyand hemoglobin decrease during radiotherapy have nopredictive value for the outcome of rectal cancer.Stage,grading,R status(free radial margins),type of surgery,CEA levels,and gender have predictive value for theoutcome of rectal cancer. | Christian Weissenberger Geissler Michael Otto Florian Barke Annette Henne Karl von Plehn Georg Rein Alex Müller Christine Bartelt Susanne Henke Michael | 2006 | World Journal of Gastroenterology2006，12，12： | 4 |
| 6 | Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?显示文摘AIM: To define the (co-)expression pattern of target receptor-tyrosine-kinases (RTK) in human gastric adenocarcinoma. METHODS: The (co-)expression pattern of VEGFR1-3,PDGFRα/b and EGFR1 was analyzed by RT-PCR in 51 human gastric adenocarcinomas. In addition,IHC staining was applied for confirmation of expression and analysis of RTK localisation. RESULTS: The majority of samples revealed a VEGFR1 (98%),VEGFR2 (80%),VEGFR3 (67%),PDGFRα (82%) and PDGFRβ(82%) expression,whereas only 62% exhibited an EGFR1 expression. 78% of cancers expressed at least four out of six RTKs. While VEGFR1-3 and PDGFRα revealed a predominantly cytoplasmatic staining in tumor cells,accompanied by an additional nuclear staining for VEGFR3 ,EGFR1 was almost exclusively detected on the membrane of tumor cells. PDGFRβ was restricted to stromal pericytes,which also depicted a PDGFRα expression.receptor-tyrosine-kinases coexpression in gastric adenocarcinoma and might therefore encourage an application of multiple-target RTK-inhibitors within a combination therapy. | Daniel Drescher Markus Moehler Ines Gockel Kirsten Frerichs Annett Müller Friedrich Dünschede Thomas Borschitz Stefan Biesterfeld Martin Holtmann Thomas Wehler Andreas Teufel Kerstin Herzer Thomas Fischer Martin R Berger Theodor Junginger Peter R Galle Carl C Schimanski | 2007 | World Journal of Gastroenterology2007，13，26： | 4 |
| 7 | A striking local esophageal cytokine expression profile in eosinophilic esophagitis显示文摘 | Carine Blanchard Emily M. Stucke Beatriz Rodriguez-Jimenez Karen Burwinkel Margaret H. Collins Annette Ahrens Eileen S. Alexander Bridget K. Buckmeier Butz Sean C. Jameson Ajay Kaul James P. Franciosi Jonathan P. Kushner Philip E. Putnam J. Pablo Abonia M | 2010 | The Journal of Allergy and Clinical Immunology2010，，1： | 3 |
| 8 | Endoscopic findings in patients with Schatzki rings:Evidence for an association with eosinophilic esophagitis显示文摘AIM:To investigate endoscopic findings in patients with Schatzki rings(SRs) with a focus on evidence for eosinophilic esophagitis(EoE).METHODS:We consecutively approached all adult patients scheduled for elective outpatient upper endoscopy for a variety of indications at the German Diagnostic Clinic,Wiesbaden,Germany between July 2007 and July 2010.All patients with endoscopically diagnosed SRs,defined as thin,symmetrical,mucosal structures located at the esophagogastric junction,were prospectively registered.Additional endoscopic findings,clinical information and histopathological findings with a focus on esophageal eosinophilia(≥ 20 eosinophils/high power field) were recorded.The criteria for active EoE were defined as:(1) eosinophilic tissue infiltration ≥ 20 eosinophils/hpf;(2) symptoms of esophageal dysfunction;and(3) exclusion of other causes of esophageal eosinophilia.Gastroesophageal reflux disease was excluded by proton pump inhibitor treatment prior to endoscopy.The presence of ≥ 20 eosinophils/hpf in esophageal biopsies in patients that did not fulfil the criteria of EoE was defined as esophageal hypereosinophilia.RESULTS:A SR was diagnosed in 171(3.3%;128 males,43 females,mean age 66 ± 12.9 years) of the 5163 patients that underwent upper gastrointestinalendoscopy.Twenty of the 116 patients(17%) from whom esophageal biopsies were obtained showed histological hypereosinophilia(≥ 20 eosinophils/hpf).Nine of these patients(8 males,1 female,mean age 49 ± 10 years) did not fulfill all diagnostic criteria of EoE,whereas in 11(9%) patients with ≥ 20 eosinophils/hpf,a definite diagnosis of EoE was made.Three of the 11 patients(27%) with definite EoE had no suspicious endoscopic features of EoE.In contrast,in the 25 patients in whom EoE was suspected by endoscopic features,EoE was only confirmed in 7(28%) patients.Patients with EoE were younger(mean age 41.5 ± 6.5 vs 50.5 ± 11.5 years,P = 0.012),were more likely to have a history of allergies(73% vs 29%,P = 0.007) and complained more often of dysphagia(91% vs 34%,P = 0.004) and food impaction(36% vs 6%,P = 0.007) than patients without EoE.Endoscopically,additional webs were found significantly more often in patients with EoE than in patients without EoE(36% vs 11%,P = 0.04).Furthermore,the SR had a tendency to be narrower in patients with EoE than in those without EoE(36% vs 18%,P = 0.22).The percentage of males(73% vs 72%,P = 1.0) and frequency of heartburn(27% vs 27%,P = 1.0) were not significantly different in both groups.The 9 patients with esophageal hypereosinophilia that did not fulfil the diagnostic criteria of EoE were younger(mean age 49 ± 10 years vs 58 ± 6 years,P = 0.0008) and were more likely to have a history of allergies(78% vs 24%,P = 0.003) than patients with < 20 eosinophils/hpf.Predictors of EoE were younger age,presence of dysphagia or food impaction and a history of allergies.CONCLUSION:A significant proportion of patients with SRs also have EoE,which may not always be suspected according to other endoscopic features. | Michaela Müller Alexander J Eckardt Annette Fisseler-Eckhoff Susanne Haas Ines Gockel Till Wehrmann | 2012 | World Journal of Gastroenterology2012，18，47： | 2 |
| 9 | Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease显示文摘 | Velandai Srikanth Annette Maczurek Thanh Phan Megan Steele Bernadette Westcott Damian Juskiw Gerald Münch | 2009 | Neurobiology of Aging2009，，5： | 2 |
| 10 | 基于单片机的MRI仿真脉冲发生器的设计显示文摘在功能磁共振实验设计中,需要利用脉冲发生器模拟磁共振设备的扫描脉冲以实现精确的时间控制。本文提出了一种基于单片机PIC16F877的MRI仿真低频脉冲发生器设计方案,用于需要精准时序的功能磁共振实验设计。本装置的核心部分是单片机PIC16F877,通过单片机的软件来产生不同频率和占空比的脉冲波。通过选择开关来实现脉冲周期和占空比的调节;同时用数码管LED显示脉冲的相应周期。由此装置得到的脉冲幅度为5V,可调周期范围是0.5s^8.0s,精度为0.1s。占空比有20%、30%、40%、50%4种可调。这种MRI仿真脉冲发生器使用简单方便,产生的低频脉冲精度高并且稳定性好,能很好的模拟功能磁共振实验中需要的脉冲信号。 | 彭涛 侯文生 郑小林 吴小鹰 沈珊 Annette M Sterr | 2009 | 微计算机信息2009，25，2： | 2 |
| 11 | Estimating the Global Public Health Implications of Electricity and Coal Consumption显示文摘 | Gohlke Julia M Thomas Reuben Woodward Alistair Campbell-Lendrum Diarmid Prüss-üstün Annette Hales Simon Portier Christopher J | 2011 | Environmental Health Perspectives2011，，6： | 2 |
| 12 | 基于fMRI的力量调节速度相关神经兴奋模式的初步研究显示文摘目的研究视觉引导的握力运动力量调节速度快慢所激活脑功能区的异同。方法15例正常受试者右手进行四种模式(由视觉反馈增益和力量变化速度两个因素组合而成)握力运动,同时进行BOLDfMRI扫描,比较四种模式脑激活的异同。结果四种模式握力运动均可激活初级躯体感觉运动区(SMC),双侧前运动区(PMC)、辅助运动区(SMA)、小脑、基底节(BG),对侧后顶叶(PPC),Brodmann40等。其中,随着力量调节速度的提高,SMC激活强度、范围都提高,而BG恰好相反,SMA激活强度提高但范围缩小,小脑表现不明显。结论SMC对力量输出的快速调节作用明显;PPC,PMC参与了将视觉信息转化成力量输出这一过程;BG在快速运动时受到SMC、SMA的制约。 | 牟宗霞 侯文生 郑小林 吴小鹰 沈珊 Annette M Sterr 彭承琳 | 2008 | 中国医学影像技术2008，24，3： | 2 |
| 13 | Immunisation against PCV2 structural protein by DNA vaccination of mice显示文摘 | Ren S K Annette M B Tine H F | 2004 | Vaccine2004，22，： | 1 |
| 14 | Experimental studies of transgastric gallbladder surgery: cholecystectomy and cholecystogastric anastomosis (videos) <ce:link locator='fx1'/>显示文摘 | Per-Ola Park Maria Bergstr?m Keiichi Ikeda Annette Fritscher-Ravens Paul Swain | 2005 | Gastrointestinal Endoscopy2005，，4： | 1 |
| 15 | Employee Involvement and Participation:Developing the Concept of Institutional Embeddedness Using WERS2004显示文摘 | Annette C Mick M Suterc J | | 0，，10： | 1 |
| 16 | Atypical cerebral dominance predictions and tests of the right shift theory显示文摘 | ANNETT M ALEXANDER MP | 1996 | Neuropsychologia1996，34，12： | 1 |
| 17 | Determinants of life quality in school-age children with cerebral palsy显示文摘 | Annette M Micbeal S Peter R etal | 2007 | Journal of Pediatrics2007，151，5： | 1 |
| 18 | Impact of pollen on hu- man health: more than allergen carriers 显示文摘 | Claudia T H Anna K Annette M | 2003 | Allergy Immunol2003，131，： | 1 |
| 19 | Solid lipod nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism显示文摘 | Annette M Schwarz C Mehnert W | 1998 | Eur J Pharm Biopharm1998，45，2： | 1 |
| 20 | A PhaseⅠ dose-escalation study of regorafenib (BAY 73-4506),an inhibitor of oncogenic,angiogenic,and stromal kinases,in patients with advanced solid tumors显示文摘 | Klaus M Annette F Simone S | | 0，，09： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员